Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
Journal of Clinical Oncology · 10.03.2026 · 44 (8) · 698-708
DOI: 10.1200/jco-25-02087 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2026. Verfasst von Rawan G Faramand und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
Clinical trials and real-world evidence have established the benefit of chimeric antigen receptor (CAR) T-cell therapy to reduce progression of hematologic malignancies and, in some settings, increase overall survival. However, recent studies have highlighted that patients in long-term remission remain at risk of morbidity and nonrelapse mortality, primarily because of infections and subsequent myeloid malignancies. In addition, these patients may also be survivors of chemotherapy, radiation, and/or stem-cell transplant, with broad survivorship needs. Here, we provide a roadmap for the care of patients in long-term remission after CAR-T-cell therapies and discuss avenues for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
ORCID-Profile: Michael D Jain
Zitieren
APA
Faramand, R. G., Xie, Z., & Jain, M. D. (2026). Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. Journal of Clinical Oncology, 44(8), 698-708. https://doi.org/10.1200/jco-25-02087
Vancouver
Faramand RG, Xie Z, Jain MD. Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. Journal of Clinical Oncology. 2026;44(8):698-708. doi:10.1200/jco-25-02087
BibTeX
@article{Faramand2026,
author = {Faramand, Rawan G and Xie, Zhuoer and Jain, Michael D},
title = {Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {8},
pages = {698--708},
doi = {10.1200/jco-25-02087}
}
EUVIMED